Is Moderna (MRNA) a Buy Right Now?
A plain-English read on Moderna stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Moderna is currently trading at $64.46, reflecting a 1.8% daily change. It sits above its 200-day average of $47.64, which is a common metric used to identify a long-term upward trend. When the price stays above this average, it suggests that the broader market sentiment remains positive.
The stock is approaching its recent resistance, or ceiling, of $65.53. Meanwhile, its RSI, a gauge of whether a stock has moved too far, too fast, sits at 63.3. This indicates healthy momentum without being excessively overbought, supporting the current buy stance as the stock moves within its 52-week range.
Should you buy Moderna stock?
A buy decision here reflects the current upward trend and price positioning. Investors should note that the stock is nearing its $65.53 ceiling, which may influence future movement. Always consider your own risk tolerance before entering any position.
Is MRNA a good stock for beginners?
Moderna is a large company, but it can experience significant price swings, as shown by its wide 52-week range of $22.28 to $85.6. Beginners should be aware that the negative P/E ratio, or the price paid for each dollar of earnings, reflects current lack of profitability.
What's driving MRNA right now
The stock price is currently trading above its 200-day average of $47.64.
The stock is nearing its recent resistance level of $65.53.
The RSI of 63.3 shows steady movement without being overextended.
The company currently reports a negative P/E ratio of -13.2.
What Moderna actually does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna by the numbers
Wall Street consensus on MRNA is Hold. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Moderna's earnings history
Earnings per share for Moderna's last 4 reported financial years, as filed — EPS has fallen over that span. We don't hold analyst consensus estimates for these periods, so no beat-or-miss judgement is shown.
| Period end | EPS reported |
|---|---|
| 2025-12-31 | -7.26 |
| 2024-12-31 | -9.27 |
| 2023-12-31 | -12.34 |
| 2022-12-31 | 21.26 |
Who owns Moderna?
Institutions — pension funds, asset managers, index providers — hold 80.4% of MRNA, and the concentration matters: the largest single holder alone controls 12.99% of the company.
| Holder | Shares | % held |
|---|---|---|
| 51.86M | 12.99% | |
| 30.60M | 7.66% | |
| 23.21M | 5.81% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Moderna insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Moderna, 3 were sales and 0 were open-market purchases; the other 3 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-06 | AWARD / VEST | 751.7K | $14.4M | |
| 2026-08-05 | SELL | 499.2K | $28.7M | |
| 2026-07-15 | SELL | 53.3K | $3.6M |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading MRNA?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. 4 disclosures name MRNA — filed by 2 separate members and worth $18K–$95K combined (filings report bands, never exact amounts). 0 purchase-side, 4 sale-side, most recently on 2021-07-22.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2021-07-22 | SELL | $1,001 - $15,000 | |
| 2021-01-29 | SELL | $15,001 - $50,000 | |
| 2021-01-29 | SELL | $1,001 - $15,000 |
Names withheld — plus 1 more record not shown.
See which membersWith the price holding above its 200-day average and showing steady momentum, Moderna currently aligns with a buy signal.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice MRNA risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about MRNA
Should I buy MRNA stock?+
The current data shows a buy signal as the price sits at $64.46, well above the 200-day average of $47.64.
Is MRNA a good long-term investment?+
Long-term trends are supported by the price staying above the 200-day average, though the negative P/E ratio of -13.2 is a factor to monitor.
Is MRNA a buy or a sell?+
Based on the upward trend and current momentum, the data points to a buy.
Is MRNA overvalued?+
The stock is trading at $64.46, which is within its 52-week range of $22.28 to $85.6.
Is MRNA a good stock for beginners?+
Beginners should be cautious of the volatility seen in the 52-week range of $22.28 to $85.6.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Moderna (MRNA) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-17 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.